- The FDA has lifted the clinical hold on Immunome Inc's IMNM Investigational New Drug (IND) application for its antibody cocktail (IMM-BCP-01) to treat COVID-19.
- Immunome previously announced that the FDA had placed its IND application on clinical hold due to a request for further information related to the preparation and administration of IMM-BCP-01 at clinical sites.
- In response, Immunome provided the FDA with a comprehensive report detailing the necessary information.
- Related: Immunome Shares Seesaw After COVID-19 Antibody Cocktail Works Against Live Omicron Virus.
- "We believe in the potential of IMM-BCP-01 and its ability to aid in the ongoing fight against SARS-CoV-2, especially as the new variants continue," said Purnanand Sarma, President & CEO of Immunome. "We are pleased to report that the clinical hold has now been lifted. We look forward to advancing the program into the clinic.
- Price Action: IMNM shares are down 6.56% at $3.99 during the market session on the last check Friday.
Loading...
Loading...
IMNMImmunome Inc
$9.633.88%
Edge Rankings
Momentum
12.66
Growth
Not Available
Quality
Not Available
Value
8.85
Price Trend
Short
Medium
Long
© 2025 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in